Navigation Links
FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
Date:12/10/2007

New class of ApoA-I/HDL drugs to reverse atherosclerosis enters the clinic

TSX Exchange Symbol: RVX

CALGARY, Dec. 10 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it has received approval by the US Food and Drug Administration (FDA) to initiate a Phase 1a clinical trial of oral RVX-208 in the USA. RVX-208 is a novel first-in-class small molecule that increases the production of ApoA-I and HDL. ApoA-I is regarded as the critical cardioprotective protein for the treatment of cardiovascular diseases.

The Phase I clinical trial is taking place at a leading US contract research organization. The trial consist of three arms, an ascending single dose, a fed and fasted dose effect study, and a 7-day ascending multiple dose that will enroll a total of 70-80 healthy volunteers. The primary objective of the trial is to evaluate oral RVX-208 in healthy adult subjects for safety, tolerability, and pharmacokinetics. Results from this Phase 1a trial will be used for optimizing dosing for future trials including our Phase 1b trial.

Gregory S. Wagner, PhD, Senior Vice President, Preclinical Development of Resverlogix, stated that, "RVX-208 possesses a very favorable pharmacological and pharmaceutical profile. This compound is an excellent choice to be the first drug candidate from our preclinical pipeline, our research and development team has worked aggressively to rapidly advance it into clinical development."

"This field has been developing for 50 years. In multiple human and animal studies over-expression or repeated infusion of ApoA-I inhibit progression and induce regression of atherosclerosis in both animals and humans," stated Dr. Jan Johansson, MD, PhD. Senior Vice President of Clinical Affairs of Resverlogix. "We have identified a way to increase the endogenous production of ApoA-I via a small molecule drug. The initiation of this clinical trial is a milestone for the fi
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
11. Resverlogix is Presenting at IAS HDL Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , March 30, 2015  Spherix Incorporated (Nasdaq: ... to the fostering and monetization of intellectual property, ...  Case No. 3:13-cv-03494-M and  Spherix v. Uniden , ... District Court for the Northern District of ... Spherix v. Verizon, Case No. 1:14-cv-00721-GBL-TCB, ...
(Date:3/30/2015)... CARDIFF, UK, and BELLINGHAM, Washington, USA (PRWEB) March 29, ... energy projects in Europe and the United States and ... programme highlights planned for SPIE Optics + Optoelectronics ... will feature over 700 technical presentations in 17 conferences ... international society for optics and photonics , the event ...
(Date:3/30/2015)... March 30, 2015 Immunocore ... drugs to treat cancer, viral infections and autoimmune ... John Bell , the Regius Professor of ... Office for the Strategic Coordination of Health Research, ...      (Photo: http://photos.prnewswire.com/prnh/20150330/736483 ) ...
(Date:3/30/2015)... , March 30, 2015  Naldemedine, an investigational ... by Shionogi & Co., Ltd., met its primary ... (COMPOSE I) for the treatment of opioid-induced constipation ... receiving opioid therapy. Study results showed that naldemedine ... improved the frequency of spontaneous bowel movement (SBM) ...
Breaking Biology Technology:Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
... meet the needs of an entire laboratory , ... Steege Michael Rahilly ,Stratagene , Stratagene is introducing ... a new temperature cycler with,interchangeable blocks for ... of tools and are currently available in a 40-well, ...
... the tempest thermoshaker , Jeff Braman ,Stratagene , , ... tempest Thermoshaker , , ... 96-deep-well, round-bottom plate were used to cultivate ... and mid-log phase rates of bacterial growth, ...
... of difficult-to-express proteins , Tamara Kleber-Janke ... Research Center Borstel, Germany , By using ... E. coli, argU, ileY, and leuW tRNA ... of difficult proteins affected by,poor codon usage: ...
Cached Biology Technology:New Temperature Cycler Features Interchangeable Blocks 2New Temperature Cycler Features Interchangeable Blocks 3New Temperature Cycler Features Interchangeable Blocks 4New Temperature Cycler Features Interchangeable Blocks 5High-Throughput Cultivation of Bacterial Clones 2High-Throughput Cultivation of Bacterial Clones 3High-Level Expression of Peanut Allergens Affected by Rare Codon Usage 2High-Level Expression of Peanut Allergens Affected by Rare Codon Usage 3High-Level Expression of Peanut Allergens Affected by Rare Codon Usage 4
(Date:3/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... CNBC television starting March 30 th . ... New York markets. ... excited about our new ad campaign following the recent initial ...
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... a news clip that aired this week on ... . In a segment "The Next Great Thing", ... ,a new way to pay, and ,a really big breakthrough ...
(Date:3/16/2015)... HANOVER, Germany , March 16, 2015 /PRNewswire/ ... DERMALOG Identification Systems GmbH will present groundbreaking innovations ... Hanover, Germany . ... DERMALOG,s latest biometric innovation is well at ... the next generation e-gate made in ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... /PRNewswire-iReach/ -- All-natural premium nutritional supplement Focus ... mind-boosting brain supplement intended to give students, athletes, ... boost that they need. In preparation of its ... its national advertising campaign with a full-page ad ...
... obesity associated with the burgeoning industrial and service sectors in ... factor in reducing the negative impact on women,s health. ... in the journal BMC Public Health , found that ... occupations were twice as likely to be ,centrally obese, ...
... was arriving in Hong Kong when the engine control thrusts ... landinginjuring dozens. The potential culprit? Contaminated fuel. The ... becomes more popular and as distribution and supply systems use ... of fuels. A professor and student team at ...
Cached Biology News:New Brain Supplement Focus Boost Launches, Boosting Alertness, Memory and Focus 2Education protects women from the obesity associated with urban living 2University of Tennessee professor and student develop device to detect biodiesel contamination 2
Donor feline serum and plasma...
Collected from sexually mature, mixed sex, mixed breed cats. Physiochemical constituents are measured to ensure lot-to-lot consistency....
Complete cell culture media with cytokines...
... ultra-compact pump available in single head (T2-04 SH) ... use in portable air and gas applications. Delivering ... well in environments where DC operation, high performance, ... critical., Offers ultra-compact size, long life, and ...
Biology Products: